The enchanting canvas of CAR technology: Unveiling its wonders in non-neoplastic diseases.
Jinhui Shu, Wei Xie, Zhaozhao Chen...
https://pubmed.ncbi.nlm.nih.gov/38608709/Actively Recruiting
Led by Cabaletta Bio · Updated on 2026-10-15
40
Participants Needed
13
Research Sites
N/A
Total Duration
Researchers are studying the safety and appropriate dosing of special immune cells called autologous CART cells, specifically DSG3-CAART and CABA-201, in adults with active pemphigus vulgaris PV, a painful autoimmune disease causing blisters on skin and mucous membranes. This phase 12 open-label trial includes patients with mucosal and mucocutaneous forms of PV, focusing on those not well controlled by standard treatments. Participants receive either DSG3-CAART through single or multiple intravenous infusions at different dose levels, or CABA-201 as a single intravenous infusion, sometimes combined with preconditioning treatments like cyclophosphamide and fludarabine. The DSG3-CAART part of the study is no longer enrolling, while the CABA-201 sub-study is ongoing. These treatments are being evaluated for safety and how they affect the disease. During the trial, participants undergo various assessments including monitoring for adverse events up to three months for DSG3-CAART and up to 28 days or longer for CABA-201. Researchers track immune cell levels, autoantibody changes, disease activity scores, clinical remission status, and other biomarkers for up to 36 months or longer. The study includes regular evaluations to understand the treatment effects and safety over time.
CONDITIONS
A Phase 1/2, Open-label, Safety and Dosing Study of Autologous CART Cells (Desmoglein 3 Chimeric Autoantibody Receptor T Cells [DSG3-CAART] or CD19-specific Chimeric Antigen Receptor T Cells [CABA-201]) in Subjects With Active, Pemphigus Vulgaris (RESET-PV)
C
Cabaletta Bio
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Cabaletta Bio
Lead Sponsor
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
| Factors | Investigational CAR‑T therapy | Standard first‑line therapy (rituximab + steroids) |
|---|---|---|
| What it is | Experimental autologous CAR‑T cell therapies targeting DSG3 or CD19 designed to eliminate autoantibody‑producing B cells in patients with active pemphigus vulgaris | First‑line systemic therapy using anti‑CD20 rituximab in combination with short‑course corticosteroids |
| Role in trial | Single‑group, sequential dose‑escalation study evaluating safety and dosing of investigational CAR‑T therapies | Usual care outside trial; not evaluated within this study |
| Primary use | Treatment of active pemphigus vulgaris unresponsive to prior immunosuppressive therapy | Induction of disease remission in new or active pemphigus vulgaris cases |
| How it is given or performed | Single intravenous infusion of autologous CAR‑T cells after sequential dose escalation; may include preconditioning depending on cohort | Two intravenous infusions of rituximab given two weeks apart plus short‑course systemic corticosteroids |
| Evidence status | Preliminary feasibility and safety shown in small cohort without lymphodepletion, with clinical response and B‑cell depletion | High rates of complete remission off therapy at two years compared to steroids alone |
| Important risks | Potential risks include cytokine release syndrome and infusion‑related effects; early data report one grade 1 CRS, no neurotoxicity | Risks include infusion reactions, infections and immunosuppression |
| Important limitations | Data limited to small number of early‑phase patients; long‑term efficacy, optimal dosing, durability, and broader safety remain unknown | Some patients relapse or are refractory; long‑term corticosteroid exposure carries risks |
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Varies by participant
Participants receive intravenous infusions of either DSG3-CAART at varying doses or a single infusion of CABA-201, sometimes with preconditioning drugs, depending on the study part.
Multiple visits for infusions and monitoring
Duration - Up to 36 months
Participants are monitored for safety and treatment effects through regular assessments, including blood tests and disease activity evaluations, for up to 36 months or longer.
Regular follow-up visits
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
SEQUENTIAL
Primary Purpose
TREATMENT
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Jinhui Shu, Wei Xie, Zhaozhao Chen...
https://pubmed.ncbi.nlm.nih.gov/38608709/Daniel Nunez, Jason Stadanlick, Thomas Furmanak...
https://pubmed.ncbi.nlm.nih.gov/42201777/Cabaletta Bio
Lead Sponsor